Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

ClinicalTrials.gov ID: NCT01272232

Public ClinicalTrials.gov record NCT01272232. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with type 2 diabetes. Treatment will be added onto subject's pre-trial background diabetes treatment of either diet and exercise only or single compound oral antidiabetic drug (OAD) treatment (metformin, sulphonylurea \[SU\] or glitazone) or combination OAD treatment (metformin, sulphonylurea or glitazone). The duration of the trial will be 56 weeks followed by a 12 week observational follow-up period.

Study identification

NCT ID
NCT01272232
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
846 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2011
Primary completion
Dec 31, 2012
Completion
Jan 24, 2013
Last update posted
Dec 28, 2017

2011 – 2013

United States locations

U.S. sites
67
U.S. states
29
U.S. cities
60
Facility City State ZIP Site status
Novo Nordisk Investigational Site Vestavia Hills Alabama 35209
Novo Nordisk Investigational Site Peoria Arizona 85381
Novo Nordisk Investigational Site Jonesboro Arkansas 72401
Novo Nordisk Investigational Site Concord California 94520
Novo Nordisk Investigational Site Long Beach California 90807
Novo Nordisk Investigational Site Los Angeles California 90057
Novo Nordisk Investigational Site Mission Hills California 91345
Novo Nordisk Investigational Site Spring Valley California 91978
Novo Nordisk Investigational Site Tustin California 92780
Novo Nordisk Investigational Site Arvada Colorado 80005
Novo Nordisk Investigational Site Brooksville Florida 34601
Novo Nordisk Investigational Site Clearwater Florida 33765
Novo Nordisk Investigational Site Hollywood Florida 33021
Novo Nordisk Investigational Site Kissimmee Florida 34741
Novo Nordisk Investigational Site Plantation Florida 33324
Novo Nordisk Investigational Site Tampa Florida 33603
Novo Nordisk Investigational Site Atlanta Georgia 30318
Novo Nordisk Investigational Site Columbus Georgia 31904
Novo Nordisk Investigational Site Roswell Georgia 30076
Novo Nordisk Investigational Site Honolulu Hawaii 96814
Novo Nordisk Investigational Site Meridian Idaho 83642
Novo Nordisk Investigational Site Chicago Illinois 60607
Novo Nordisk Investigational Site Chicago Illinois 60611-5975
Novo Nordisk Investigational Site Springfield Illinois 62711
Novo Nordisk Investigational Site Topeka Kansas 66606
Novo Nordisk Investigational Site Lexington Kentucky 40503
Novo Nordisk Investigational Site Louisville Kentucky 40213
Novo Nordisk Investigational Site New Orleans Louisiana 70121
Novo Nordisk Investigational Site Columbia Maryland 21045
Novo Nordisk Investigational Site Hyattsville Maryland 20782
Novo Nordisk Investigational Site Southfield Michigan 48034-7661
Novo Nordisk Investigational Site Minneapolis Minnesota 55416
Novo Nordisk Investigational Site St Louis Missouri 63110
Novo Nordisk Investigational Site Lawrenceville New Jersey 08648
Novo Nordisk Investigational Site Toms River New Jersey 08755-8050
Novo Nordisk Investigational Site Albany New York 12206
Novo Nordisk Investigational Site Endwell New York 13760
Novo Nordisk Investigational Site Asheville North Carolina 28803
Novo Nordisk Investigational Site Greensboro North Carolina 27408
Novo Nordisk Investigational Site Hickory North Carolina 28602
Novo Nordisk Investigational Site Morehead City North Carolina 28557
Novo Nordisk Investigational Site Raleigh North Carolina 27609
Novo Nordisk Investigational Site Salisbury North Carolina 28144
Novo Nordisk Investigational Site Wilmington North Carolina 28401
Novo Nordisk Investigational Site Winston-Salem North Carolina 27103
Novo Nordisk Investigational Site Cincinnati Ohio 45255
Novo Nordisk Investigational Site Dayton Ohio 45439
Novo Nordisk Investigational Site Oklahoma City Oklahoma 73104
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19107
Novo Nordisk Investigational Site Anderson South Carolina 29621
Novo Nordisk Investigational Site Moncks Corner South Carolina 29461
Novo Nordisk Investigational Site Bristol Tennessee 37620
Novo Nordisk Investigational Site Chattanooga Tennessee 37404
Novo Nordisk Investigational Site Chattanooga Tennessee 37411
Novo Nordisk Investigational Site Nashville Tennessee 37212
Novo Nordisk Investigational Site Austin Texas 78728
Novo Nordisk Investigational Site Austin Texas 78731
Novo Nordisk Investigational Site Dallas Texas 75230
Novo Nordisk Investigational Site Dallas Texas 75231
Novo Nordisk Investigational Site Dallas Texas 75246
Novo Nordisk Investigational Site San Antonio Texas 78207-5209
Novo Nordisk Investigational Site San Antonio Texas 78240
Novo Nordisk Investigational Site San Antonio Texas 78258
Novo Nordisk Investigational Site Salt Lake City Utah 84102
Novo Nordisk Investigational Site St. George Utah 84790
Novo Nordisk Investigational Site Newport News Virginia 23606
Novo Nordisk Investigational Site Olympia Washington 98502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 94 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01272232, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 28, 2017 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01272232 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →